Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes.

The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. 

DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Therapeutics

Diamyd Medical

Ulf Hannelius

Niklas Axelsson

Martina Widman

Anton Lindqvist

Diamyd Medical

Org chart

Teams

Offices